NewGenIvf Group Limited
NewGenIvf Group Limited (NIVF) Stock Competitors & Peer Comparison
See (NIVF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NIVF | $1.80 | +2.86% | 3.3M | -0.08 | -$23.04 | N/A |
| UNH | $304.86 | -0.83% | 276.1B | 13.20 | $23.09 | +2.79% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | N/A |
| CVS | $71.21 | -0.13% | 90.3B | 19.83 | $3.59 | +3.75% |
| CI | $300.76 | -1.18% | 80.2B | 16.49 | $18.23 | +1.94% |
| ELV | $314.00 | -0.81% | 70.8B | 13.33 | $23.58 | +2.13% |
| HUM | $297.20 | -0.77% | 35.8B | 22.76 | $13.06 | +1.19% |
| CNC | $29.08 | -1.12% | 14.3B | 7.06 | $4.12 | N/A |
| MOH | $175.17 | +0.42% | 9.5B | 8.63 | $20.29 | N/A |
| OSCR | $16.71 | -0.54% | 4.2B | -24.21 | -$0.69 | N/A |
Stock Comparison
NIVF vs UNH Comparison August 2025
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 3.3M. In comparison, UNH has a market cap of 276.1B. Regarding current trading prices, NIVF is priced at $1.80, while UNH trades at $304.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of -0.08, whereas UNH's P/E ratio is 13.20. In terms of profitability, NIVF's ROE is +0.03%, compared to UNH's ROE of +0.22%. Regarding short-term risk, NIVF is more volatile compared to UNH. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check UNH's competition here
NIVF vs ANTM Comparison August 2025
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 3.3M. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, NIVF is priced at $1.80, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of -0.08, whereas ANTM's P/E ratio is 18.99. In terms of profitability, NIVF's ROE is +0.03%, compared to ANTM's ROE of +0.18%. Regarding short-term risk, NIVF is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for NIVF.Check ANTM's competition here
NIVF vs CVS Comparison August 2025
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 3.3M. In comparison, CVS has a market cap of 90.3B. Regarding current trading prices, NIVF is priced at $1.80, while CVS trades at $71.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of -0.08, whereas CVS's P/E ratio is 19.83. In terms of profitability, NIVF's ROE is +0.03%, compared to CVS's ROE of +0.06%. Regarding short-term risk, NIVF is more volatile compared to CVS. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check CVS's competition here
NIVF vs CI Comparison August 2025
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 3.3M. In comparison, CI has a market cap of 80.2B. Regarding current trading prices, NIVF is priced at $1.80, while CI trades at $300.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of -0.08, whereas CI's P/E ratio is 16.49. In terms of profitability, NIVF's ROE is +0.03%, compared to CI's ROE of +0.12%. Regarding short-term risk, NIVF is more volatile compared to CI. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check CI's competition here
NIVF vs ELV Comparison August 2025
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 3.3M. In comparison, ELV has a market cap of 70.8B. Regarding current trading prices, NIVF is priced at $1.80, while ELV trades at $314.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of -0.08, whereas ELV's P/E ratio is 13.33. In terms of profitability, NIVF's ROE is +0.03%, compared to ELV's ROE of +0.13%. Regarding short-term risk, NIVF is more volatile compared to ELV. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check ELV's competition here
NIVF vs HUM Comparison August 2025
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 3.3M. In comparison, HUM has a market cap of 35.8B. Regarding current trading prices, NIVF is priced at $1.80, while HUM trades at $297.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of -0.08, whereas HUM's P/E ratio is 22.76. In terms of profitability, NIVF's ROE is +0.03%, compared to HUM's ROE of +0.09%. Regarding short-term risk, NIVF is more volatile compared to HUM. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check HUM's competition here
NIVF vs CNC Comparison August 2025
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 3.3M. In comparison, CNC has a market cap of 14.3B. Regarding current trading prices, NIVF is priced at $1.80, while CNC trades at $29.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of -0.08, whereas CNC's P/E ratio is 7.06. In terms of profitability, NIVF's ROE is +0.03%, compared to CNC's ROE of +0.08%. Regarding short-term risk, NIVF is more volatile compared to CNC. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check CNC's competition here
NIVF vs MOH Comparison August 2025
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 3.3M. In comparison, MOH has a market cap of 9.5B. Regarding current trading prices, NIVF is priced at $1.80, while MOH trades at $175.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of -0.08, whereas MOH's P/E ratio is 8.63. In terms of profitability, NIVF's ROE is +0.03%, compared to MOH's ROE of +0.25%. Regarding short-term risk, NIVF is more volatile compared to MOH. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check MOH's competition here
NIVF vs OSCR Comparison August 2025
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 3.3M. In comparison, OSCR has a market cap of 4.2B. Regarding current trading prices, NIVF is priced at $1.80, while OSCR trades at $16.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of -0.08, whereas OSCR's P/E ratio is -24.21. In terms of profitability, NIVF's ROE is +0.03%, compared to OSCR's ROE of -0.14%. Regarding short-term risk, NIVF is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for NIVF.Check OSCR's competition here
NIVF vs ALHC Comparison August 2025
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 3.3M. In comparison, ALHC has a market cap of 3.1B. Regarding current trading prices, NIVF is priced at $1.80, while ALHC trades at $15.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of -0.08, whereas ALHC's P/E ratio is -57.70. In terms of profitability, NIVF's ROE is +0.03%, compared to ALHC's ROE of -0.44%. Regarding short-term risk, NIVF is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for NIVF.Check ALHC's competition here
NIVF vs CLOV Comparison August 2025
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 3.3M. In comparison, CLOV has a market cap of 1.4B. Regarding current trading prices, NIVF is priced at $1.80, while CLOV trades at $2.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of -0.08, whereas CLOV's P/E ratio is -33.06. In terms of profitability, NIVF's ROE is +0.03%, compared to CLOV's ROE of -0.13%. Regarding short-term risk, NIVF is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for NIVF.Check CLOV's competition here
NIVF vs BHG Comparison August 2025
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 3.3M. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, NIVF is priced at $1.80, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of -0.08, whereas BHG's P/E ratio is -0.12. In terms of profitability, NIVF's ROE is +0.03%, compared to BHG's ROE of -0.65%. Regarding short-term risk, NIVF is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for NIVF.Check BHG's competition here
NIVF vs BMGL Comparison August 2025
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 3.3M. In comparison, BMGL has a market cap of 37.4M. Regarding current trading prices, NIVF is priced at $1.80, while BMGL trades at $1.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of -0.08, whereas BMGL's P/E ratio is 199.00. In terms of profitability, NIVF's ROE is +0.03%, compared to BMGL's ROE of +0.32%. Regarding short-term risk, NIVF is more volatile compared to BMGL. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check BMGL's competition here
NIVF vs MRAI Comparison August 2025
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 3.3M. In comparison, MRAI has a market cap of 24.9M. Regarding current trading prices, NIVF is priced at $1.80, while MRAI trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of -0.08, whereas MRAI's P/E ratio is -0.50. In terms of profitability, NIVF's ROE is +0.03%, compared to MRAI's ROE of +0.41%. Regarding short-term risk, NIVF is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for NIVF.Check MRAI's competition here
NIVF vs IVF Comparison August 2025
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 3.3M. In comparison, IVF has a market cap of 1M. Regarding current trading prices, NIVF is priced at $1.80, while IVF trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of -0.08, whereas IVF's P/E ratio is -0.01. In terms of profitability, NIVF's ROE is +0.03%, compared to IVF's ROE of -5.98%. Regarding short-term risk, NIVF is less volatile compared to IVF. This indicates potentially lower risk in terms of short-term price fluctuations for NIVF.Check IVF's competition here
NIVF vs MGLN Comparison August 2025
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 3.3M. In comparison, MGLN has a market cap of 0. Regarding current trading prices, NIVF is priced at $1.80, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of -0.08, whereas MGLN's P/E ratio is 8.49. In terms of profitability, NIVF's ROE is +0.03%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, NIVF is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check MGLN's competition here
NIVF vs GTS Comparison August 2025
NIVF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NIVF stands at 3.3M. In comparison, GTS has a market cap of 0. Regarding current trading prices, NIVF is priced at $1.80, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NIVF currently has a P/E ratio of -0.08, whereas GTS's P/E ratio is 10.41. In terms of profitability, NIVF's ROE is +0.03%, compared to GTS's ROE of +0.07%. Regarding short-term risk, NIVF is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for NIVF.Check GTS's competition here